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Abstract
Background and Purpose: The goal of palliative care is symptom control
in patients with advanced disease and improvement of their quality of life.
Materials and Methods: Pain assessment can be done through numer-
ous rating scales. It is important to quantify pain so that health care provid-
ers can provide the most sufficient pain therapy and determine the effective-
ness of it.
Results: Morphine is the »gold standard« as pain medication in pallia-
tive care. Patients receiving palliative care often require frequent escalations
in opioid dosage to attain good pain control. If the patient’s pain cannot be
controlled by using opioids co-adjuvant analgesics should be added.
Conclusions: In pain control therapy we should apply the cancer pain al-
gorithm named »analgesic elevator« which is suggested by IASP.
INTRODUCTION
Prevalence data indicates that there are currently about 18 millionpeople living with cancer world-wide. At least 5,5 million have can-
cer pain. Prevalence of pain rates from 30 to 40 per cent in patients on
active anticancer therapy and from 70 to 90 per cent in patients with ad-
vanced disease. (1) Pain impairs the patient's and caregiver's quality of life
(QoL), worsens the prognosis and is still commonly under treated (2).
The goals of palliative care are to control symptoms in patients with
advanced disease and enhance their quality of life. No patient at the
end of life should have unrelieved pain (3). With the pharmacological
approach, about 90–95% of patients get pain relief. Non-pharmacologi-
cal approaches, neurosurgical or anaesthetic techniques may also re-
lieve pain. This article addresses the pharmacological aspect of pain
management.
Facts about pain
Many patients do not receive adequate control of their symptoms.
Although education and training in the management of pain have in-
creased for physicians and nurses, many patients do not receive ade-
quate analgesia. More than 70% of cancer patients report pain (4) and
more than 36% of patients with metastatic disease have pain severe
enough to impair function (5). The presence of pain usually implies a
pathological process; in patients with cancer idiopathic or psychologi-
cal pain is very rare (6). Pain not only adversely affects the quality of life
of patients, but also can be psychologically devastating because it can be
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Clinical experience
Repeated comprehensive pain assessments are the cor-
nerstone of adequate pain management. A complete his-
tory and a physical examination, with emphasis on the
patient’s symptoms are obtained, including information
regarding the location, intensity, radiation, aggravating
factors, timing, quality, and meaning of the pain. Medi-
cations and treatments are reviewed, and a psychosocial
history is taken.
Pain assessment
The intensity or severity of the pain must first be
quantified. Pain rating scales that have been used for
more than a decade allow patients to quantify their pain
so that health care providers can determine the effective-
ness of the therapy. The most commonly used is the nu-
meric rating scale. Pain is rated on a scale of 0–10, with
8–10 being severe pain, 4–7 moderate pain, and 1–3 mild
pain (8) Other scales, including the visual analogue scale
and the verbal rating scale, are available to quantify the
patient's pain. Because most patients have variable toler-
ance to pain, patients should frequently be asked if the
pain is interfering with their daily activities and some pa-
tients are unwilling to admit to having increased pain be-
cause this may be associated with progression of their un-
derlying disease. This question often provides insight
into the level of pain.
Pain assessment tools also give us various aspects of
pain: location, quality, onset, duration etc. Precisely lo-
cating the discomfort can also help in determining the
type and nature of the pain.
Pain management in the elderly is complicated by dif-
ficulties in pain assessment. Elderly patients may under
report pain, and pain reports from cognitively impaired
patients may be incomplete, but also valid.
All patients if possible should complete a standardised
questionnaire or undergo a structured interview. The
key to good pain management in patients with advanced
disease is thorough and frequent assessment. The entire
palliative care team can be useful in monitoring a pa-
tient’s pain. (9) Patients are often unable to adequately
rate their pain (9) and it may be necessary to monitor be-
haviour that could be indicative of pain in some patients
(10) Behaviour such as mood swings, agitation, restless-
ness, and increased fatigue may all signify an increase in
the patient’s pain. But also patients can be sleepless,
withdrawn, depressed or irritable when experiencing
pain. Physicians and nurses have to be familiar with
these manifestations and to recognise them as pain man-
ifestation.
Actiology of pain
Pain may arise from different aetiology. It can be due
to the direct effects of the cancer or caused by treatment
of the disease. Surgery, radiation, and chemotherapy may
all result in pain. The patient may also have chronic un-
derlying disease that directly causes or contributes to
pain. Visceral pain arises from direct stimulation of affer-
ent nerves due to tumour infiltration of the soft tissue or
viscera (11) This pain tends to be poorly localised and of-
ten ill defined. In cancer patients, visceral pain may be
caused not only by direct tumour infiltration, but also by
variable conditions such as constipation, radiation, or
chemotherapy. Somatic pain in cancer patients is gener-
ally due to soft tissue inflammation or to metastatic dis-
ease of the bone (12). Neuropathic pain is generally de-
scribed as burning or electrical in nature. This type of
pain is due to neuronal injury either by the effects of
treatment or by tumour invasion. For example, cisplatin,
vincristine, and procarbazine can be harmful to nerves.
Neuropathic pain may not always be responsive to opioid
therapy.
Pain management
Symptom control in the home setting may differ from
that provided in a more traditional setting such as a hos-
pital or nursing home. Pain management must be re-
sponsive to the patient’s changing symptoms, and care
must be taken to respect the family’s wishes and limita-
tions. Family members are often reluctant to give injec-
tions or administer medicines rectally. Breakthrough me-
dications are often withheld for fear of getting their loved
one »addicted« to opioids.
Treatment with analgesic drugs is the mainstay of
cancer pain treatment (13). WHO Expert Committee on
Cancer Pain Relief and Active Supportive Care over two
decades ago proposed a useful approach to drug selection
for cancer pain which has become known as the WHO
analgesic ladder (Figure 1).
WHO method for cancer pain relief when combined
with appropriate dosing guidelines provides adequate
relief to roughly 70-90 per cent of patients (14).
Non-opioid drugs comprise paracetamol (acetami-
nophen), the non-steroidal anti-inflammatory drugs
(NSAIDs) and nefopam. Non-opioids have a »ceiling«
effect and therefore if a patient's pain is inadequately
controlled and the maximum dose has been reached,
then the drugs must be changed, supplemented with
opioids, or an adjuvant drug added (15).
Opioid use
Opioid receptors (mu, kappa, delta) are found in sev-
eral areas of the brain, particularly in the periaqueductal
grey matter and throughout the spinal cord. Based on
their interactions with the various receptor subtypes, opioid
compounds can be divided into agonist, agonist-antago-
nist and antagonist classes (16). The agonist opioid drugs
have no clinically relevant ceiling effect to analgesia, in
contrast to both the partial agonists and agonist-antago-
nists drugs (16). Jacox et al. (17) found that 75%–85% of
patients received adequate pain control with oral, rectal,
and transdermal drugs. Unfortunately, patients, their fa-
milies, and some physicians may have unexpressed sig-
nificant concerns and misconceptions about opioids. The
physician must explain that patients with malignant tu-
mours who take opioids do not become addicts, and »that
we have lots of medications for the latter«.
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Morphine is often referred to as the »gold standard« in
palliative care because it is effective, inexpensive, and
easy to titrate, and it can administered using many routes
including oral, rectal, parenteral, subcutaneous, and spi-
nal. Morphine is a potent mu agonist drug that was first
induced into clinical use 200 years ago. Today is the pro-
totype opioid step III of the »analgesic ladder«. Morphine
and morphine-like agonists (methadone, pethidine, hy-
dromorphone, levorphanol, oxycodone, oxymorphone,
fentanyl and phenazocine) are widely used to manage
cancer pain while mixed agonist-antagonist analgesics
(pentazocine, butorphanol and nalbuphine) play a very
limited role in the management of chronic cancer pain
(18).
The goal of good pain management is to minimise
both the patient’s pain and the need for breakthrough
medication. When comfortable on a given dosing regi-
men, the patient should be converted to a long-acting
medication. All patients should have access to break-
through medication since up to two thirds of patients
with well-controlled chronic pain have transitory break-
through pain (19).
The most common side effects of opioids are sedation,
constipation, emesis, confusion, hallucinations, urinary
retention, dizziness and uncommon respiratory depres-
sion. Clinically important respiratory depression is a very
rare effect in the cancer patient whose opioid dose has
been titrated against pain. Close monitoring of the pa-
tient’s symptoms through frequent reassessment dictates
the need for titration of the opioid (20).
Patients receiving palliative care often require fre-
quent escalations in opioid dosage to attain good pain
control. Foley et al. (21). found that 20% of patients re-
quired three switches of their medication before finding
an effective dose. Reassessment by the health care team is
necessary after every medication change. Opioid use in
older patients should be monitored closely. Older pa-
tients may require lower doses of opioids, and therefore
these medications should be used cautiously in this patient
population (22). Opioids should never be discontinued
abruptly in patients receiving chronic opioids as this may
cause an acute withdrawal reaction.
Tolerance and Addiction
Tolerance is defined as the progressive decline of the
potency of an opioid with continued use. Patients may
also develop tolerance to the side effects of an opioid. Pa-
tients are often reluctant to increase the dose of their
medication because they fear that the tolerance they have
developed will lessen the effectiveness of the opioids at a
later date. These patients should be assured that toler-
ance can develop as a normal result of opioid use and that
a simple dose escalation is all that is usually required for
additional pain control.
Fear of addiction (psychological dependence) is a ma-
jor consideration limiting the use of opioids. The devel-
opment of physical dependence and tolerance are dis-
tinct from the behavioural pattern seen in some
individuals and described as »addiction« (23).
Surveys of cancer patients and burn patients receiving
chronic opioids during a long period, suggest that medi-
cal use of opioids rarely, if ever, leads to drug abuse or iat-
rogenic opioid addiction.
Infusion Therapy and Spinal Analgesia
If the patient’s pain cannot be controlled by escalating
doses of medication via the oral, rectal, or transdermal
routes, more invasive therapy may be instituted. Opioids
may be given via this route and may be titrated rapidly by
patient-controlled analgesia. The subcutaneous route is
limited due to variability in absorption of medications in
each individual patient, depending on the amount of
subcutaneous tissue. Venous access is a more effective
method of delivering larger doses of opioids when rapid
escalation is required. Medications are not limited by the
concentration, and the variation in absorption is not a
factor. However, not all patients have easily obtainable
venous access, and central or peripherally inserted cen-
tral venous catheter (PICC) line placement is often re-
quired. Spinal analgesia should be considered for pa-
tients with pain that is poorly responsive to conventional
routes. This route should also be considered for patients
with poorly controlled pain or for those who cannot tol-
erate the side effects of oral opioids.
Adjuvant analgesics (coanalgesics)
Adjuvant analgesics (coanalgesics) are administered
with primary analgesics to enhance pain relief, treat pain
that is refractory to the analgesics, or allow reduction of
the analgesic dose for the purpose of limiting side effects
(24).
The adjuvant analgesics comprise an extraordinarily
diverse group of drug classes (antidepressants, cortico-
steroids, anticonvulsants, local anaesthetics, neuroleptics
etc.) and many of these drugs act like multipurpose
analgetics. Focus on neuropathic pain as a target for
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Figure 1. The three step analgesic ladder.
adjuvant analgesics in the palliative care setting derives
from the relatively poor response of these pain syndromes
to opioid drugs (25) and neuropathic pain is the usual in-
dication for trial of a multipurpose adjuvant analgesic.
Cancer pain algorithm
Based on these data an alternative cancer pain algo-
rithm known as »analgesic elevator« is suggested by IASP
(26). »Analgesic elevator« selects the strength of the opioid
analgesic according to the current severity of pain:
1. For mild pain, non-opioid analgesic treatment should
be initiated. If pain is not adequately controlled, then low
doses of »strong« opioids should be added and titrated.
2. For moderate pain, low doses of »strong« opioids
should be initiated and titrated, with or without non-
-opioids.
3. The treatment of severe pain obviously requires the
immediate use of »strong« opioids, with or without non-
-opioids.
4. Invasive procedures should be considered as an al-
ternative or adjunct to pharmacotherapy at any stage of
disease with moderate or severe cancer pain.
5. Adjuvant drugs should be used for all stages when
indicated.
6. »Weak« opioids should be dropped in the treatment
of cancer, other than in countries where »strong« opioids
are not readily available.
Although many studies support this suggested algo-
rithm, further validation should be provided by prospec-
tive studies in broad populations of patients with cancer
pain (26).
CONCLUSIONS
Pharmacologic therapy is the mainstay of pain man-
agement in patients with advanced disease. The majority
of patients can attain good pain control with the use of
opioids and adjuvant medications. Simple means of ad-
ministration such as oral, transdermal, or rectal can be
used in managing the majority of pain syndromes. Prin-
ciples of good pain management include a thorough ini-
tial assessment and frequent reassessment to monitor the
efficacy of treatment and the onset of side effects. Opioids
need to be titrated to attain good pain control. Many cancer
patients have more than one pain syndrome, and multi-
ple medications are often indicated. Frequent assess-
ment, rapid intervention, and appropriate use of opioids
and their adjuvants are requisites for adequate pain con-
trol and optimal quality of life.
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